Share Price and Basic Stock Data
Last Updated: December 4, 2025, 1:12 am
| PEG Ratio | 16.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jubilant Pharmova Ltd operates in the pharmaceuticals sector, with a current share price of ₹1,080 and a market capitalization of ₹17,259 Cr. The company’s revenue from operations stood at ₹7,404 Cr for the trailing twelve months (TTM), reflecting a steady growth trajectory compared to ₹6,282 Cr in the previous fiscal year. Quarterly sales have shown resilience, with the most recent quarter (Sep 2023) recording sales of ₹1,680 Cr, slightly up from ₹1,587 Cr in Jun 2023. This upward trend in revenue is indicative of the company’s ability to adapt to market demands. Over the past year, sales have consistently hovered around the ₹1,500 Cr mark per quarter, highlighting a robust operational performance. The operating profit margin (OPM) stood at 15%, which is in line with industry averages, showing effective cost management. Overall, the company has demonstrated a solid revenue generation capability, reflecting its strategic initiatives and market positioning in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Jubilant Pharmova reported a net profit of ₹457 Cr for the TTM, translating to an earnings per share (EPS) of ₹28.88. This represents a significant recovery from a net loss of ₹65 Cr in the previous fiscal year. The company’s profitability metrics have shown improvement, with a return on equity (ROE) of 9.55% and a return on capital employed (ROCE) of 9.54%. The interest coverage ratio (ICR) of 5.12x indicates a comfortable ability to meet interest obligations, which is vital for maintaining financial health. In terms of operational efficiency, the cash conversion cycle (CCC) was recorded at 65 days, demonstrating effective management of working capital. The net profit margin reached 11.56%, marking a notable increase from the previous year, which is a positive sign for investors. However, the fluctuating OPM, which reached a peak of 18% in Mar 2025, suggests that while profitability is improving, there remains room for better efficiency and cost control in operations.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jubilant Pharmova reflects a stable financial position, with total assets amounting to ₹12,584 Cr and total liabilities at ₹12,584 Cr as of Mar 2025. The company recorded reserves of ₹6,576 Cr, which provide a cushion for future expansions and investments. Borrowings stood at ₹2,883 Cr, indicating a manageable debt level relative to equity. The long-term debt to equity ratio is at 0.34, suggesting low leverage and financial risk. The current ratio of 1.65 indicates sufficient liquidity to cover short-term obligations. Additionally, the price-to-book value (P/BV) ratio of 2.25x suggests that the stock is trading at a premium relative to its book value, reflecting investor confidence in its future growth prospects. However, the total debt to equity ratio of 0.38 signals that while the company is not overly leveraged, its reliance on debt financing could be a concern in times of rising interest rates.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Jubilant Pharmova reveals a diversified ownership structure, with promoters holding 47.67% of the shares. Foreign institutional investors (FIIs) account for 16.56%, while domestic institutional investors (DIIs) hold 10.53%. Public ownership is at 24.60%, showcasing a broad base of retail investors. Over the past year, there has been a gradual decline in promoter holding from 50.67% in Jun 2025, which may raise questions about long-term commitment. However, the increase in DII ownership from 1.62% in Dec 2022 to 10.53% in Sep 2025 indicates growing institutional confidence in the company’s prospects. The number of shareholders stood at 93,336, reflecting a stable investor interest. While the reduction in promoter stake could be viewed as a red flag, the overall shareholder diversity may provide resilience against market volatility.
Outlook, Risks, and Final Insight
Looking ahead, Jubilant Pharmova’s solid revenue growth and improving profitability metrics suggest a positive outlook for the company. However, risks such as fluctuating operational margins and a declining promoter stake may pose challenges. Additionally, the pharmaceutical sector is subject to regulatory scrutiny, which could impact the company’s operational flexibility. The company’s ability to maintain its current trajectory will depend on effective cost management and strategic investments in R&D. If it can capitalize on growth opportunities while mitigating risks, Jubilant Pharmova may enhance its market position. Conversely, failure to address operational inefficiencies or adverse regulatory changes could hinder progress. Overall, the company stands at a crossroads, with potential for significant growth balanced against inherent sector challenges that require vigilant management.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Jubilant Pharmova Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 109 | 247/84.3 | 30.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,347 Cr. | 399 | 479/192 | 90.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 30.5/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,566.25 Cr | 1,174.15 | 52.64 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,452 | 1,600 | 1,552 | 1,678 | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 |
| Expenses | 1,259 | 1,384 | 1,408 | 1,459 | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 |
| Operating Profit | 192 | 216 | 144 | 219 | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 |
| OPM % | 13% | 14% | 9% | 13% | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% |
| Other Income | 11 | -44 | 10 | 21 | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 |
| Interest | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 |
| Depreciation | 95 | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 |
| Profit before tax | 69 | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 |
| Tax % | 32% | 87% | 285% | 16% | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% |
| Net Profit | 47 | 5 | -16 | -100 | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 |
| EPS in Rs | 2.96 | 0.34 | -0.98 | -6.15 | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 |
Last Updated: August 1, 2025, 6:40 pm
Below is a detailed analysis of the quarterly data for Jubilant Pharmova Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,901.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,929.00 Cr. (Mar 2025) to 1,901.00 Cr., marking a decrease of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,611.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,584.00 Cr. (Mar 2025) to 1,611.00 Cr., marking an increase of 27.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 290.00 Cr.. The value appears to be declining and may need further review. It has decreased from 345.00 Cr. (Mar 2025) to 290.00 Cr., marking a decrease of 55.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 15.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 53.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 98.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 206.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 52.00 Cr..
- For Tax %, as of Jun 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 34.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 102.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 49.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.46. The value appears to be declining and may need further review. It has decreased from 9.64 (Mar 2025) to 6.46, marking a decrease of 3.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,762 | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 7,404 |
| Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 6,192 |
| Operating Profit | 999 | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,211 |
| OPM % | 17% | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 16% |
| Other Income | -173 | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 18 |
| Interest | 337 | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 218 |
| Depreciation | 281 | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 376 |
| Profit before tax | 207 | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 635 |
| Tax % | 34% | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | |
| Net Profit | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 457 |
| EPS in Rs | 6.84 | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 28.88 |
| Dividend Payout % | 43% | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -128.99% | 1067.50% | 48.58% | 10.26% | -8.99% | 55.63% | -6.90% | -50.60% | -115.74% | 212.31% | 1045.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1196.49% | -1018.92% | -38.32% | -19.25% | 64.62% | -62.54% | -43.69% | -65.14% | 328.05% | 832.90% |
Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | -10% |
| 3 Years: | 10% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 8% |
| 3 Years: | 48% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 2,611 | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 6,576 |
| Borrowings | 4,395 | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 | 2,883 |
| Other Liabilities | 1,842 | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 | 4,047 |
| Total Liabilities | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
| Fixed Assets | 5,099 | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 7,354 |
| CWIP | 472 | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 2,344 |
| Investments | 34 | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 45 |
| Other Assets | 3,259 | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 | 3,778 |
| Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
Below is a detailed analysis of the balance sheet data for Jubilant Pharmova Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,576.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,239.00 Cr. (Mar 2025) to 6,576.00 Cr., marking an increase of 337.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,883.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,731.00 Cr. (Mar 2025) to 2,883.00 Cr., marking an increase of 152.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,047.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,598.00 Cr. (Mar 2025) to 4,047.00 Cr., marking an increase of 449.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 13,521.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,176.00 Cr. (Mar 2025) to 7,354.00 Cr., marking an increase of 2,178.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,344.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,630.00 Cr. (Mar 2025) to 2,344.00 Cr., marking a decrease of 1,286.00 Cr..
- For Investments, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,735.00 Cr. (Mar 2025) to 3,778.00 Cr., marking an increase of 43.00 Cr..
- For Total Assets, as of Sep 2025, the value is 13,521.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
Notably, the Reserves (6,576.00 Cr.) exceed the Borrowings (2,883.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 995.00 | 606.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -2.00 | 776.00 | 898.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 |
| Inventory Days | 200 | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 |
| Days Payable | 107 | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 |
| Cash Conversion Cycle | 144 | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 |
| Working Capital Days | -92 | 12 | 4 | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 |
| ROCE % | 11% | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund | 550,339 | 0.37 | 20.61 | 550,339 | 2025-04-22 15:56:56 | 0% |
| Nippon India Nifty Smallcap 250 Index Fund | 46,210 | 0.24 | 1.73 | 46,210 | 2025-04-22 17:25:29 | 0% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 29,012 | 0.24 | 1.09 | 29,012 | 2025-04-22 17:25:29 | 0% |
| SBI Nifty Smallcap 250 Index Fund | 21,292 | 0.24 | 0.8 | 21,292 | 2025-04-22 15:56:56 | 0% |
| Motilal Oswal Nifty 500 Index Fund | 3,170 | 0.02 | 0.12 | 3,170 | 2025-04-22 15:56:56 | 0% |
| Edelweiss Nifty Smallcap 250 Index Fund | 980 | 0.24 | 0.04 | 980 | 2025-04-22 15:56:56 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 827 | 0.38 | 0.03 | 827 | 2025-04-22 17:25:29 | 0% |
| Groww Nifty Total Market Index Fund | 178 | 0.02 | 0.01 | 178 | 2025-04-22 17:25:29 | 0% |
| Motilal Oswal Nifty 500 ETF | 139 | 0.02 | 0.01 | 139 | 2025-04-22 15:56:56 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 52.99 | 4.87 | -3.83 | 26.00 | 52.48 |
| Diluted EPS (Rs.) | 52.99 | 4.86 | -3.83 | 26.00 | 52.48 |
| Cash EPS (Rs.) | 76.29 | 27.25 | 29.98 | 50.55 | 73.70 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Revenue From Operations / Share (Rs.) | 457.88 | 424.23 | 394.85 | 385.08 | 383.10 |
| PBDIT / Share (Rs.) | 77.88 | 61.36 | 51.20 | 73.35 | 88.83 |
| PBIT / Share (Rs.) | 54.55 | 37.19 | 16.38 | 49.37 | 66.91 |
| PBT / Share (Rs.) | 62.09 | 9.27 | 0.97 | 40.23 | 54.01 |
| Net Profit / Share (Rs.) | 52.96 | 3.08 | -4.85 | 26.57 | 51.78 |
| NP After MI And SOA / Share (Rs.) | 53.13 | 4.88 | -3.83 | 26.00 | 52.51 |
| PBDIT Margin (%) | 17.00 | 14.46 | 12.96 | 19.04 | 23.18 |
| PBIT Margin (%) | 11.91 | 8.76 | 4.14 | 12.82 | 17.46 |
| PBT Margin (%) | 13.56 | 2.18 | 0.24 | 10.44 | 14.09 |
| Net Profit Margin (%) | 11.56 | 0.72 | -1.22 | 6.90 | 13.51 |
| NP After MI And SOA Margin (%) | 11.60 | 1.15 | -0.97 | 6.75 | 13.70 |
| Return on Networth / Equity (%) | 13.41 | 1.41 | -1.12 | 7.78 | 17.62 |
| Return on Capital Employeed (%) | 8.13 | 6.08 | 2.77 | 9.35 | 13.53 |
| Return On Assets (%) | 6.58 | 0.66 | -0.54 | 4.14 | 9.37 |
| Long Term Debt / Equity (X) | 0.34 | 0.58 | 0.57 | 0.46 | 0.54 |
| Total Debt / Equity (X) | 0.38 | 0.62 | 0.63 | 0.55 | 0.54 |
| Asset Turnover Ratio (%) | 0.59 | 0.59 | 0.59 | 0.01 | 0.37 |
| Current Ratio (X) | 1.65 | 2.05 | 2.12 | 2.20 | 2.81 |
| Quick Ratio (X) | 1.13 | 1.37 | 1.34 | 1.42 | 1.74 |
| Inventory Turnover Ratio (X) | 5.98 | 1.36 | 1.26 | 0.00 | 1.44 |
| Dividend Payout Ratio (NP) (%) | 9.48 | 103.24 | -130.60 | 19.23 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.58 | 17.34 | 16.15 | 10.00 | 0.00 |
| Earning Retention Ratio (%) | 90.52 | -3.24 | 230.60 | 80.77 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.42 | 82.66 | 83.85 | 90.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.12 | 3.56 | 4.33 | 8.03 | 7.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.99 | 1.80 | 0.89 | 3.91 | 4.17 |
| Enterprise Value (Cr.) | 15436.46 | 11426.80 | 6827.69 | 8114.60 | 12743.97 |
| EV / Net Operating Revenue (X) | 2.13 | 1.70 | 1.09 | 1.32 | 2.09 |
| EV / EBITDA (X) | 12.54 | 11.79 | 8.38 | 6.95 | 9.01 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| Retention Ratios (%) | 90.51 | -3.24 | 230.60 | 80.76 | 0.00 |
| Price / BV (X) | 2.25 | 1.65 | 0.82 | 1.16 | 2.28 |
| Price / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| EarningsYield | 0.05 | 0.01 | -0.01 | 0.06 | 0.07 |
After reviewing the key financial ratios for Jubilant Pharmova Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 52.99, marking an increase of 48.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.86 (Mar 24) to 52.99, marking an increase of 48.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 76.29. This value is within the healthy range. It has increased from 27.25 (Mar 24) to 76.29, marking an increase of 49.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 457.88. It has increased from 424.23 (Mar 24) to 457.88, marking an increase of 33.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 77.88. This value is within the healthy range. It has increased from 61.36 (Mar 24) to 77.88, marking an increase of 16.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 54.55. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 54.55, marking an increase of 17.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.09. This value is within the healthy range. It has increased from 9.27 (Mar 24) to 62.09, marking an increase of 52.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 52.96. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 52.96, marking an increase of 49.88.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 53.13. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 53.13, marking an increase of 48.25.
- For PBDIT Margin (%), as of Mar 25, the value is 17.00. This value is within the healthy range. It has increased from 14.46 (Mar 24) to 17.00, marking an increase of 2.54.
- For PBIT Margin (%), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 8.76 (Mar 24) to 11.91, marking an increase of 3.15.
- For PBT Margin (%), as of Mar 25, the value is 13.56. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 13.56, marking an increase of 11.38.
- For Net Profit Margin (%), as of Mar 25, the value is 11.56. This value exceeds the healthy maximum of 10. It has increased from 0.72 (Mar 24) to 11.56, marking an increase of 10.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 11.60, marking an increase of 10.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 1.41 (Mar 24) to 13.41, marking an increase of 12.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.13. This value is below the healthy minimum of 10. It has increased from 6.08 (Mar 24) to 8.13, marking an increase of 2.05.
- For Return On Assets (%), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 0.66 (Mar 24) to 6.58, marking an increase of 5.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.34, marking a decrease of 0.24.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.38, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has decreased from 2.05 (Mar 24) to 1.65, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.13, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.98, marking an increase of 4.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 20. It has decreased from 103.24 (Mar 24) to 9.48, marking a decrease of 93.76.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 20. It has decreased from 17.34 (Mar 24) to 6.58, marking a decrease of 10.76.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.52. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.52, marking an increase of 93.76.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.42. This value exceeds the healthy maximum of 70. It has increased from 82.66 (Mar 24) to 93.42, marking an increase of 10.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.56 (Mar 24) to 5.12, marking an increase of 1.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 1.80 (Mar 24) to 2.99, marking an increase of 1.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,436.46. It has increased from 11,426.80 (Mar 24) to 15,436.46, marking an increase of 4,009.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.13, marking an increase of 0.43.
- For EV / EBITDA (X), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 11.79 (Mar 24) to 12.54, marking an increase of 0.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For Retention Ratios (%), as of Mar 25, the value is 90.51. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.51, marking an increase of 93.75.
- For Price / BV (X), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 2.25, marking an increase of 0.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
- Net Profit Margin: 11.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.7 (Industry average Stock P/E: 52.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.56%
Fundamental Analysis of Jubilant Pharmova Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bhartiagram, Amroha District Uttar Pradesh 244223 | investors@jubl.com http://www.jubilantpharmova.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shyam S Bhartia | Chairman |
| Mr. Hari S Bhartia | Co-Chairman |
| Mr. Priyavrat Bhartia | Managing Director |
| Mr. Arjun Shanker Bhartia | Joint Managing Director |
| Mr. Arvind Chokhany | WholeTime Director & Group CFO |
| Mr. R Kumar | Whole Time Director |
| Mr. Vivek Mehra | Independent Director |
| Mr. Sushil Kumar Roongta | Independent Director |
| Mr. Arun Seth | Independent Director |
| Ms. Sudha Pillai | Independent Director |
| Dr. Ashok Misra | Independent Director |
| Mr. S Sridhar | Independent Director |
| Mr. Shirish G Belapure | Independent Director |
Jubilant Pharmova Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹703.45 |
| Previous Day | ₹716.75 |
FAQ
What is the intrinsic value of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's intrinsic value (as of 04 December 2025) is 1102.60 which is 2.09% higher the current market price of 1,080.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 17,259 Cr. market cap, FY2025-2026 high/low of 1,265/802, reserves of ₹6,576 Cr, and liabilities of 13,521 Cr.
What is the Market Cap of Jubilant Pharmova Ltd?
The Market Cap of Jubilant Pharmova Ltd is 17,259 Cr..
What is the current Stock Price of Jubilant Pharmova Ltd as on 04 December 2025?
The current stock price of Jubilant Pharmova Ltd as on 04 December 2025 is 1,080.
What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jubilant Pharmova Ltd stocks is 1,265/802.
What is the Stock P/E of Jubilant Pharmova Ltd?
The Stock P/E of Jubilant Pharmova Ltd is 34.7.
What is the Book Value of Jubilant Pharmova Ltd?
The Book Value of Jubilant Pharmova Ltd is 414.
What is the Dividend Yield of Jubilant Pharmova Ltd?
The Dividend Yield of Jubilant Pharmova Ltd is 0.46 %.
What is the ROCE of Jubilant Pharmova Ltd?
The ROCE of Jubilant Pharmova Ltd is 9.54 %.
What is the ROE of Jubilant Pharmova Ltd?
The ROE of Jubilant Pharmova Ltd is 9.55 %.
What is the Face Value of Jubilant Pharmova Ltd?
The Face Value of Jubilant Pharmova Ltd is 1.00.